BMS-986393
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for BMS-986393, covering 2026-04-14 to 2026-04-14. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) [Phase 3]